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Abstract
Background: HLA-DRB1 allele polymorphisms have been reported to be associated with hepatocellular carcinoma
susceptibility, but the results of these previous studies have been inconsistent. The purpose of the present study
was to explore whether specific HLA-DRB1 alleles (DRB1*07, DRB1*12, DRB1*15) confer susceptibility to
hepatocellular carcinoma.
Methods: Case-control studies on HLA-DRB1 alleles association with HCC were searched up to January 2010
through a systematic review of the literature. The odds ratios (ORs) of HLA-DRB1 allele distributions in patients with
hepatocellular carcinoma were analyzed against healthy controls. The meta-analysis software REVMAN 5.0 was
applied for investigating heterogeneity among individual studies and for summarizing all the studies. Meta-analysis
was performed using fixed-effect or random-effect methods, depending on absence or presence of significant
heterogeneity.
Results: Eight case-control studies were included in the final analysis. Among the 3 HLA-DRB1 alleles studied,
DRB1*07 and DRB1*12 were significantly associated with the risk of HCC in the whole populations (OR = 1.65, 95%
CI: 1.08-2.51, P = 0.02 and OR = 1.59, 95% CI: 1.09-2.32, P = 0.02, respectively). No significant association was
established for DRB1*15 allele with HCC in the whole populations. Subgroup analysis by ethnicity showed that
DRB1*07, DRB1*12 and DRB1*15 alleles significantly increased the risk of hepatocellular carcinoma in Asians (OR =
2.10, 95% CI: 1.06-4.14, P = 0.03; OR = 1.73, 95% CI: 1.17-2.57, P = 0.006 and OR = 2.88, 95%CI: 1.77-4.69, P <0.001,
respectively).
Conclusion: These results support the hypothesis that specific HLA-DRB1 alleles might influence the susceptibility
of hepatocellular carcinoma. Large, multi-ethnic confirmatory and well designed studies are needed to determine
the host genetic determinants of hepatocellular carcinoma.
Background
Hepatocellular carcinoma (HCC) is linked to the interac-
tion between genetic, immunologic, environmental, diet-
ary, and life style factors. Its incidence and distribution
vary widely among ethnic groups, sex, and geographic
regions. Hepatocellular carcinoma is the third most com-
mon cause of cancer-related deaths worldwide with
about 600,000 patients dying from the disease annually
[1]. Asian countries account for nearly 78% of the
roughly 600,000 cases of hepatocellular carcinoma (HCC)
reported globally each year [2]. China alone accounts for
more than 50% of the world’s cases [3]. HBV and HCV
infection, liver cirrhosis, male gender, and old age are
important risk factors of HCC. The clustering of HCC
within families raises the possibility that genetic factors
are also involved in susceptibility to HCC.
The Major Histocompatibility Complex (MHC) plays a
key role in anti-virus and tumor defense. Human leuko-
cyte antigens (HLA) function in the regulation of
immune response to foreign antigens and discrimination
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series of closely linked genetic loci found on chromo-
some 6 [4,5]. HLA polymorphism is implicated in con-
ferring genetic susceptibility to a large number of
immune mediated diseases, including some cancers.
Given the pivotal role of HLA molecules in the immune
system, several studies have been performed to investi-
gate the association between specific HLA alleles and
HCC. However, the association between HLA-DRB1
alleles and HCC in different ethnic populations that has
been reported is controversial. Many conflicting reports
have been published to date; thus, we performed a sys-
tematic review of all of the relevant studies published in
the literature to evaluate the association between HLA-
DRB1 alleles and HCC. Our principal objectives were to
clarify the specific HLA-DRB1 alleles that conferred sus-
ceptibility to or which protected against HCC.
Methods
Search strategy
Electronic databases (PubMed, EMBASE, Cochrane
Library and China National Knowledge Infrastructure)
were used to search for all genetic association studies
evaluating the HLA-DRB1 polymorphism and HCC in
humans in all languages up to January 2010. The search
strategy was based on combinations of the terms: HLA-
DRB1 AND (Hepatocellular carcinoma or HCC) AND
(variants or polymorphism or alleles). We also per-
formed a full manual search from the bibliographies of
selected papers. We also contacted the authors of stu-
dies containing relevant information, who did not report
the results necessary for this analysis. Unpublished data
were also accepted if an abstract was available and
further information was obtained from the author.
Selection criteria
In the meta-analysis, the following inclusive selection cri-
teria were set and reviewed by two independent investi-
gators: (1) each trial is an independent case-control
study; (2) the purpose of all studies and statistical meth-
ods is similar; (3) it supplied enough information to cal-
culate the odds ratio (OR);(4) HLA-DRB1 alleles were
molecularly typed (high or low resolution level); (5) inclu-
sion of patients according to the diagnosis standard of
HCC defined in 2002, based on at least one of the follow-
ing criteria: classical histological characteristics or serum
a-fetoprotein (AFP) level higher than 400 ng/ml together
with radiological findings (ultrasound and/or CT) consis-
tent with HCC [6]. A single study, Donaldson et al, done
before 2002, was included in the meta-analysis given that
the inclusion criteria of patients were similar to the diag-
nosis standard. The following exclusive selection criteria
were set: (1) incomplete raw data; (2) repetitive reports
(if more than one version of the same study was
retrieved, only the most recent is used); (3) materials and
methods were not well-described and reliable.
Although assessment of study quality is considered
important for systematic reviews and meta-analyses,
scoring methods have been considered problematic [7]
and may not accurately assess the quality measures of
interest [8]. Therefore, we used reliability of patient
selection, molecular typing method, and statistical analy-
sis method as quality variables.
The frequency of HLA-DRB1 alleles varies according
to ethnic and racial background, with some alleles being
extremely rare. Therefore, articles were not required to
identify all alleles for inclusion.
Data extraction
The studies were independently evaluated by two
researchers. Discrepancies in the evaluations of some
studies were resolved by discussion between the
reviewers. The following data were collected from each
study: authors, publication year, journal, publication
type and language, HLA genotyping method, allele gen-
otyped, allele frequencies, numbers of cases and con-
trols, definitions criteria used for HCC, HCC sample
description, controls sample description. Allelic fre-
quency was calculated as the number of cases or con-
trols harboring at least one allele type (HLA-DRB1)
divided by the total number of chromosomes included
in each of the corresponding groups.
Statistical analysis
The literature review conformed to PRISMA statement
standards, and our research fit the minimum set of
items for reporting in systematic reviews and meta-ana-
lyses (Additional file 1). Heterogeneity was calculated by
means of Cochran’sQt e s t( a = 0.05) and Higgins’s( I
2)
tests. I
2 values of 25%, 50% and 75% were assigned as
low, moderate, and high estimates, respectively. If the
results of the Q test had no significant heterogeneity,
the Mantel-Haenszel fixed effect model (Peto method)
was used for the combination of data; If the results of
the Q test had significant heterogeneity, the Dersimo-
nian-Laird random effects model (DL method) were
used for the combination of data [9]. A pooled OR was
presented as a standard plot with 95% confidence inter-
vals (95%CIs). Meta-analysis was performed using fixed-
effect or random-effect methods, depending on absence
or presence of significant heterogeneity. As a measure
of association between HCC and HLA-DRB1 alleles, we
combined odds ratios (ORs) with 95% confidence inter-
vals (95%CIs) stratified by gene subtype of patients and
controls in a study. Funnel plots and the Egger’sr e g r e s -
sion asymmetry test were used to evaluate publication
bias [10]. All P values presented are two-tailed. To
reduce heterogeneity and to evaluate whether there was
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studies, we performed subgroup analysis according to
the ethnicity. We performed a sensitivity analysis to
assess the stability of the results by sequential omission
of individual studies. The analyses were performed using
Revman 5.0 provided by the Cochrane Collaboration.
Results
Literature assessment
Figure 1 shows the flow chart of publications identified
by the literature search. Search strategy allowed us to
identify 84 studies for potential inclusion in the meta-
analysis. Finally 8 case-control studies relating to HLA-
DRB1 alleles polymorphism and susceptibility to HCC
qualified on the basis of our selection criteria [11-18].
A total of 957 subjects were studied (including 341
patients and 616 controls). The main features of the stu-
dies included in the meta-analysis are shown in Table 1.
Among the eight studies, five studies were conduct in
Asian countries; two were conduct in European coun-
tries, and one was conduct in African countries. Mean or
median age was not stated in 4/8 reports and sex in 4/8.
HIV status was determined in only one report [12].
HLA-DRB1 alleles were molecularly typed (high or
low resolution level). Five studies used low resolution
molecular typing for HLA, while three used high resolu-
tion molecular typing for HLA. Low resolution molecu-
lar typing methods for HLA could not identify the
specific alleles. Accurate methods for HLA class II typ-
ing should involve the combination of PCR-SSOP, PCR-
SSP, and PCR-SSCP [19].
Meta-analysis: Association between HLA-DRB1 alleles
with HCC
A total of 13 HLA-DRB1 alleles were studied in the 8
case-control studies, buto n l y3a l l e l e s( D R B 1 * 0 7 ,
Potentially relevant citations 
identified for evaluation (n=84)
Full manuscripts retrieved for 
evaluation (n=12)
Studies included in meta-analysis 
(n=8)
Publications identified and screened 
(n=191)
Studies Excluded (n=107) 
76    not relevant to HLA or HCC 
28  relevant  to  treatment 
3  not human studies 
Studies Excluded (n=72) 
24  not  case-control  study 
22  only  serologic  results 
19    not relevant to HLA-DRB1 
7    not relevant to HCC   
Studies Excluded (n=4) 
3    lack of sufficient data 
1    contain duplicate information or overlaps 
Figure 1 Flow chart of article selection.
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Page 3 of 10DRB1*12, DRB1*15) was extracted from the studies to
investigate their association with HCC, which were
reported at least six of the eight case-control studies.
Statistics calculated for each study are shown in the for-
est plot (Figures 2, 3 and 4).
In the meta-analysis, overall the frequencies of HLA-
DRB1*07 allele was 20.1% (59 of 281) in HCC and
15.2% (71 of 466) in controls. The heterogeneity test
indicates that the variation of trial-specific ORs was not
statistically significant (c
2 =1 0 . 7 9 ,I
2 =5 4 % ,P=0 . 0 6
and >0.05). Under the fixed effect model, the combined
OR for the association of HLA-DRB1*07 allele with the
risk for HCC in the whole populations was determined
to be 1.65 (95% CI: 1.08-2.51; p = 0.02), and under the
random effects model was 1.77 (95%CI: 0.88-3.56; p =
0.11). In sensitivity analysis, the exclusion of individual
studies did not change this significant result, except for
exclusion of the study by Pan et al and El-Chennawi et
al, which produced a non-significant association. Sub-
group analysis by ethnicity showed that HLA-DRB1*07
allele significantly increased the risk of hepatocellular
carcinoma in Asians under the fixed effect model (OR =
2.10, 95% CI: 1.06-4.14, P = 0.03).
Overall the frequencies of HLA-DRB1*12 allele was
26.3% (74 of 281) in HCC and 16.1% (83 of 516) in con-
trols. The heterogeneity test indicates that the variation
Table 1 Characteristics of studies included in the meta-analysis
Author Year Country/
Region
Number of HCC (M/F),
age
Number of controls (M/
F), age
Number of DRB1 alleles
studied
HLA genotyping
method
Donaldson [11] 2001 Hong Kong 84(79/5),55 124(-/-), NA 13 PCR-SSOP
De Re[12] 2004 Italy 29(-/-), NA 144(-/-), NA 13 PCR-SSP
Yuan [13]
# 2004 China 10(-/-), NA 50(30/20),43.7 ± 12.9 3 PCR-SSP
López-Vázquez
[14]
2004 Spain 46(27/19),62 ± 8 48(19/29),56 ± 12 11 PCR-SSOP
Yuan [15]
# 2005 China 10(-/-), NA 50(30/20),43.7 ± 12.9 2 PCR-SSP
Kummee [16] 2007 Thai 50(38/12), 57.5 ± 14.2 100(68/32),50.8 ± 13.9 2 PCR-SSP
El-Chennawi
[17]
2008 Egypt 50(45/5),51.16 ± 6.16 50(44/6),48.88 ± 9.22 11 PCR-SSP
Pan [18] 2009 China 62(52/10),53.58 50(29/21),30.12 8 PCR-SSP
NA, not available; PCR-SSOP, PCR-sequence-specific oligonucleotides probes; PCR-SSP, PCR-sequence-specific primer;
# These two studies described different allele polymorphisms with the same subjects.
Figure 2 Meta-analysis forest plot of included studies on the association between HLA-DRB1*07 allele and HCC. Each plot shows the
effect size and precision for individual studies and for the combined effect. Filled squares are proportional in size to study weights.
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Page 4 of 10of trial-specific ORs was not statistically significant (c
2 =
9.00, I
2 = 44%, P = 0.11 and >0.05), so the fixed-effect
method was used to combine the results. The combined
OR for the association of HLA-DRB1*12 allele with the
risk for HCC in the whole populations was determined
to be 1.59 (95% CI: 1.09-2.32), and was statistically sig-
nificant (P = 0.02 and <0.05). In sensitivity analysis, the
exclusion of individual studies did not change this sig-
nificant result, except for exclusion of the study by
Donaldson, et al and Sun, et al, which produced a non-
Figure 3 Meta-analysis forest plot of included studies on the association between HLA-DRB1*12 allele and HCC. Each plot shows the
effect size and precision for individual studies and for the combined effect. Filled squares are proportional in size to study weights.
Figure 4 Meta-analysis forest plot of included studies on the association between HLA-DRB1*15 allele and HCC. Each plot shows the
effect size and precision for individual studies and for the combined effect. Filled squares are proportional in size to study weights.
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Page 5 of 10significant association. Subgroup analysis by ethnicity
showed that HLA-DRB1*12 allele significantly increased
the risk of hepatocellular carcinoma in Asians (OR =
1.73, 95% CI: 1.17-2.57, P = 0.006).
Meta-analysis for HLA-DRB1*15 allele was carried out,
but it did not show any statistical effect in the whole
populations. Subgroup analysis by ethnicity showed that
HLA-DRB1*15 allele significa n t l yi n c r e a s e dt h er i s ko f
hepatocellular carcinoma in Asians under the fixed effect
model (OR = 2.88, 95% CI: 1.77-4.69, P < 0.001).
Figures 5, 6 and 7 show the funnel plot analysis to detect
publication bias of each study for DRB1*07, DRB1*12 and
DRB1*15, respectively. The shape of the funnel plot
seemed to be asymmetrical, suggesting that publication
bias might affect the findings of our meta-analysis.
Discussion
The aim of the present study was to ascertain whether
specific HLA-DRB1 alleles are associated with the devel-
opment/protection of HCC. We analyzed the published
studies investigating the association between HLA-DRB1
alleles and HCC. Studies concerning this possible asso-
ciation have been undertaken since the early 1996s [20].
T oo u rk n o w l e d g e ,t h i si st he first published meta-
analysis investigating this association. Our meta-analysis
of eight studies revealed that DRB1*07 and DRB1*12
were significantly associated with the risk of HCC in the
whole populations (OR = 1.65, 95% CI: 1.08-2.51, P =
0.02 and OR = 1.59, 95% CI: 1.09-2.32, P = 0.02, respec-
tively). Subgroup analysis by ethnicity showed that
DRB1*07 and DRB1*12 alleles also significantly
increased the risk of hepatocellular carcinoma in Asians
(OR = 2.10, 95% CI: 1.06-4.14, P = 0.03; OR = 1.73, 95%
CI: 1.17-2.57, P = 0.006, respectively). No significant
association was established for DRB1*15 allele with
HCC in the whole populations. Subgroup analysis by
ethnicity showed that DRB1*15 alleles significantly
increased the risk of hepatocellular carcinoma in Asians
under the fixed effect model (OR =2 . 8 8 ,95% CI: 1.77-
4.69, P < 0.001).
Epidemiological survey showed that Asian countries
account for nearly 78% of hepatocellular carcinoma
(HCC) reported globally each year, and Hepatitis B
Virus (HBV) is the major etiology of HCC in these
areas. Although HBV infection plays an important role
in HCC, HBV infection alone is not sufficient for
Figure 5 Funnel plot of HLA-DRB1*07 allele and HCC to explore publication bias. OR = odds ratio; SE = standard error.
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Page 6 of 10progression to HCC. Several lines of evidence suggest
that cellular immune surveillance is important in the
control of HBV infection and the development of HCC.
In 2007, Yang and his colleagues found that HLA-
DRB1*07 were markedly higher in the HBV-infected
group among people in northwestern China (17.6% of
HBV-infected patients vs 9.3% of spontaneously cleared
controls, OR = 2.09, P < 0.05) [21]. In 2006, Zhang and
his colleagues found that the frequency of HLA-
DRB1*12 was significantly higher in the HBV persistent
group than in the recovered group among Chinese
(0.230 versus 0.063, P = 0.004, OR = 2.09) [22]. In 2003,
Amarapurpar and his colleagues found that a positive
association of HLA-DRB1*15 to persistence of HBV
among Indians (57.6 vs. 25%) [23]. As we know that
clearance of acute hepatitis B virus (HBV) infection is
associated with a vigorous CD4+ T-cell response focus-
ing on the core protein. HLA class II glycoproteins pre-
sent viral peptides to CD4+ T cells and influence the
immune responses. Binding affinities of overlapping
peptides covering the core and envelope proteins of
HBV were measured to HLA glycoproteins encoded by
some HLA-DRB1 molecules and compared with
published peptide-specific CD4+ T-cell responses [24].
So we have a hypothesis that HLA-DRB1*07, DRB1*12
and DRB1*15 alleles may be the key host factors to
determine the development of diseases from HBV infec-
tion to HCC in Asians, basing on our results that HLA-
DRB1*07, DRB1*12 and DRB1*15 alleles significantly
increased the risk of hepatocellular carcinoma in Asians.
Furthermore, the importance of environmental factors
and gene-environmental interactions in the development
of HCC should not be ignored and is beginning to be
delineated.
Moreover, HLA-DRB1 alleles polymorphism have
been reported to be associated with other cancers and
autoimmune diseases, including cervical squamous cell
carcinoma, rheumatoid arthritis, systemic lupus erythe-
matosus, autoimmune hepatitis, inflammatory bowel
disease, multiple sclerosis and type 1 diabetes, and
meta-analyses have been done for these diseases [25-31].
Additionally, because the information used in our
research was based on data from observational studies,
some limitations should be discussed in this meta-analy-
sis and the results should be considered with caution. A
primary cause for the difference in results by different
Figure 6 Funnel plot of HLA-DRB1*12 allele and HCC to explore publication bias. OR = odds ratio; SE = standard error.
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quency of HLA alleles in different populations. It is
q u i t ep o s s i b l et h a to n ee t h n i cg r o u pm a yh a v es o m e
specific alleles in development/protection of HCC com-
pared to other ethnic groups. Many studies were con-
ducted on relatively smaller samples. Insufficient
number of individuals might decrease the power to
detect a difference in the distribution of DRB1*07,
DRB1*12 and DRB1*15 alleles between HCC patients
and controls, though a true difference exist. Lack of an
association may not mean that associations do not exist.
Many studies did not control for the matching variables
in the analysis, and the possible confounders could be
among the potential causes of variation in the studies’
estimates. Different types of control groups could also
be among the potential causes of variation in the stu-
dies’ estimates. Effects of interactions in other environ-
mental/behavioral and/or viral factors may be inevitable.
A complex interplay between various genes is likely to
modulate the development of HCC rather than a single
allele. HLA genotyping techniques must be taken into
consideration because these methodologies have differ-
ent sensitivities. HLA genotyping were mainly tested for
by PCR with probe hybridization, but targets were not
always verified by sequencing. This could hinder an
effective comparison between the studies and influence
the combined results. The shape of the funnel plot
seemed to be asymmetrical, suggesting that publication
bias might affect the findings of our meta-analysis.
Furthermore, although we tried to maximize our efforts
to identify all relevant published studies in peer-
reviewed journals, it is possible that some escaped our
attention.
In spite of these, our meta-analysis also had some
advantages. First, substantial number of cases and con-
trols were pooled from different studies, which signifi-
cantly increased statistical power of the analysis.
Second, the quality of case-control studies included in
the current meta-analysis was satisfactory based on our
selection criteria. Third, the patients were phenotypic
homogeneous subjects, diagnosed either by gold stan-
dard or by biochemical and imageology combined
methods, which could reduce the heterogeneity in
some extent.
Figure 7 Funnel plot of HLA-DRB1*15 allele and HCC to explore publication bias. OR = odds ratio; SE = standard error.
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Our meta-analysis suggests that HLA-DRB1*07 and
DRB1*12 alleles are risk factors for HCC in the whole
populations, especially in the Asians; DRB1*15 allele is
only associated with an increased risk of HCC in Asians
(under the fixed effect model). However, it is necessary
to conduct large trials using standardized unbiased
methods, homogeneous HCC patients and well matched
controls, with the assessors blinded to the data. More-
over, gene-gene and gene-environment interactions
should also be considered in the analysis. Such studies
taking these factors into account may eventually lead to
a better, more comprehensive understanding of the
association between HLA-DRB1 polymorphism and
HCC.
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